JP2009538896A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538896A5
JP2009538896A5 JP2009512681A JP2009512681A JP2009538896A5 JP 2009538896 A5 JP2009538896 A5 JP 2009538896A5 JP 2009512681 A JP2009512681 A JP 2009512681A JP 2009512681 A JP2009512681 A JP 2009512681A JP 2009538896 A5 JP2009538896 A5 JP 2009538896A5
Authority
JP
Japan
Prior art keywords
oxo
methyl
dihydropyridazin
fluorobenzoyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009512681A
Other languages
English (en)
Japanese (ja)
Other versions
JP5351755B2 (ja
JP2009538896A (ja
Filing date
Publication date
Priority claimed from GBGB0610680.1A external-priority patent/GB0610680D0/en
Application filed filed Critical
Publication of JP2009538896A publication Critical patent/JP2009538896A/ja
Publication of JP2009538896A5 publication Critical patent/JP2009538896A5/ja
Application granted granted Critical
Publication of JP5351755B2 publication Critical patent/JP5351755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009512681A 2006-05-31 2007-05-25 ポリ(adp−リボース)ポリメラーゼ(parp)インヒビターとしてのピリジノン及びピリダジノン誘導体 Active JP5351755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0610680.1 2006-05-31
GBGB0610680.1A GB0610680D0 (en) 2006-05-31 2006-05-31 Therapeutic compounds
PCT/GB2007/050295 WO2007138351A2 (en) 2006-05-31 2007-05-25 Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Publications (3)

Publication Number Publication Date
JP2009538896A JP2009538896A (ja) 2009-11-12
JP2009538896A5 true JP2009538896A5 (enExample) 2013-08-22
JP5351755B2 JP5351755B2 (ja) 2013-11-27

Family

ID=36694627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512681A Active JP5351755B2 (ja) 2006-05-31 2007-05-25 ポリ(adp−リボース)ポリメラーゼ(parp)インヒビターとしてのピリジノン及びピリダジノン誘導体

Country Status (16)

Country Link
US (1) US8188084B2 (enExample)
EP (1) EP2029551B1 (enExample)
JP (1) JP5351755B2 (enExample)
KR (1) KR101529891B1 (enExample)
CN (2) CN101501006A (enExample)
AU (1) AU2007266836B2 (enExample)
BR (1) BRPI0711741B8 (enExample)
CA (1) CA2653529C (enExample)
ES (1) ES2702781T3 (enExample)
GB (1) GB0610680D0 (enExample)
IL (1) IL195113A (enExample)
MX (1) MX2008015014A (enExample)
NO (1) NO343950B1 (enExample)
NZ (1) NZ572815A (enExample)
WO (1) WO2007138351A2 (enExample)
ZA (1) ZA200809238B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0622195D0 (en) * 2006-11-08 2006-12-20 Angeletti P Ist Richerche Bio Therapeutic agents
US8268827B2 (en) * 2007-11-15 2012-09-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. Pyridazinone derivatives as PARP inhibitors
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2010125102A1 (en) * 2009-04-29 2010-11-04 Glaxo Group Limited 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en) * 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
MX342161B (es) * 2010-04-02 2016-09-19 Euroscreen Sa Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
MX367774B (es) 2011-10-03 2019-09-04 Ogeda S A N-ACIL-5,6,7, (8-SUSTITUIDO)-TETRAHIDRO- [1,2,4] TRIAZOLO [4,3-a] PIRAZINAS QUIRALES, NOVEDOSAS, COMO ANTAGONISTAS SELECTIVOS DE RECEPTOR DE NK-3; COMPOSICIÓN FARMACÉUTICA, MÉTODOS PARA USO EN TRASTORNOS MEDIADOS POR RECEPTOR DE NK-3 Y SU SÍNTESIS QUIRAL.
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN103833756B (zh) * 2012-11-26 2016-12-21 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和用途
ES2469990B1 (es) * 2012-12-19 2015-01-26 Universidade De Vigo Compuestos de estructura híbrida piridazinona ditiocarbamato con actividad antineoplásica
SG11201503670YA (en) 2012-12-31 2015-07-30 Cadila Healthcare Ltd Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative
KR102194745B1 (ko) 2013-03-13 2020-12-24 포르마 세라퓨틱스 인크. Fasn 억제용 신규 화합물 및 조성물
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
WO2014154895A1 (en) 2013-03-29 2014-10-02 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
WO2014154896A1 (en) 2013-03-29 2014-10-02 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
CA2907814C (en) 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
US10550108B2 (en) 2014-10-03 2020-02-04 Institute For Cancer Research Poly(ADP-ribose) polymerase 1 inhibitors structurally unrelated to NAD
US10472664B2 (en) 2014-10-03 2019-11-12 Institute For Cancer Research Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリInstitut Curie 癌を処置するためのDbait分子とPARPインヒビターとの組合せの使用
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
DK3448859T3 (da) 2017-03-20 2019-09-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
CN109232575B (zh) * 2017-07-10 2022-01-25 中国科学院上海药物研究所 吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
HUE062096T2 (hu) 2018-04-30 2023-09-28 Ribon Therapeutics Inc Piridazinonok PARP7-inhibitorokként
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼrの活性化
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
MX2022003254A (es) 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
WO2021087025A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021214502A1 (en) 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
IL297464A (en) 2020-04-21 2022-12-01 Idience Co Ltd Crystalline forms of phthalazinone compound
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药(上海)有限公司 作为parp7抑制剂的哒嗪酮类化合物
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
AU2022451580B2 (en) * 2022-04-01 2024-11-07 Novostar Pharmaceuticals, Ltd. Parp7 inhibitor and use thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
CN1136197C (zh) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
BR0115062A (pt) 2000-10-30 2004-02-17 Kudos Pharm Ltd Derivados de ftalazinona
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
US6750350B2 (en) * 2001-08-02 2004-06-15 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US7211779B2 (en) 2001-08-14 2007-05-01 Transchip, Inc. Pixel sensor with charge evacuation element and systems and methods for using such
EP1501822B1 (en) 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
MXPA05009661A (es) 2003-03-12 2006-03-08 Kudos Pharm Ltd Derivados de ftalazinona.
CA2518823A1 (en) * 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
CA2559552A1 (en) * 2004-03-23 2005-09-29 F. Hoffmann-La Roche Ag Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CA2563225A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
AU2005276229A1 (en) 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
KR100965006B1 (ko) * 2005-07-21 2010-06-21 에프. 호프만-라 로슈 아게 갑상선 호르몬 수용체 작용제로서 피리다진온 유도체
EP1937651B1 (en) * 2005-09-30 2008-12-24 F.Hoffmann-La Roche Ag Nnrt inhibitors
JP4611441B2 (ja) * 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
EP2032140A1 (en) * 2006-05-31 2009-03-11 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
UA97506C2 (xx) 2006-12-28 2012-02-27 Эбботт Лаборетриз Інгібітори полі(adp-рибозо)полімерази$ингибиторы поли(adp-рибозо)полимеразы
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists

Similar Documents

Publication Publication Date Title
JP2009538896A5 (enExample)
RU2405771C2 (ru) Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1
RU2503676C2 (ru) Пирролопиразиновые ингибиторы киназы
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
JP2014506929A5 (enExample)
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
RU2443706C2 (ru) Фармацевтические соединения
AU2011253057B2 (en) Nitrogen heterocyclic compounds useful as PDE10 inhibitors
JP2011500774A5 (enExample)
JP2021503004A5 (enExample)
BR112021001292A2 (pt) compostos heterobicíclicos para inibir a atividade de shp2
JP2011516512A5 (ja) 新規な置換スピロ[シクロアルキル−1,3'−インドール]−2'(1'H)−オン誘導体およびp38マイトジェン活性化タンパク質キナーゼ阻害剤としてのそれらの使用
HRP20120105T1 (hr) Aminoheterociklički spojevi
RU2012152548A (ru) Пиридоновые и азапиридоновые соединения и способы применения
JP2018522046A5 (enExample)
JP2012510998A5 (enExample)
JP2010524984A5 (enExample)
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
WO2025049746A1 (en) Compositions comprising werner syndrome helicase inhibitors and methods of using the same
AU2009218459A1 (en) Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
ME02330B (me) Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
JP2013522238A5 (enExample)
RU2009125024A (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов